Sunitinib combined with pemetrexed and carboplatin in patients with NSCLC and other advanced solid malignancies: maximum tolerated dose and safety results

被引：0
|
作者：
Chow, Laura Q. M. [1 ]
Blais, Normand [2 ]
Jonker, Derek J. [1 ]
Soulieres, Denis [2 ]
Laurie, Scott A. [1 ]
Diab, Sami G. [3 ]
Ruiz-Garcia, Ana [4 ]
Thall, Aron [4 ]
Chao, Richard [4 ]
Eckhardt, S. Gail [5 ]
Camidge, D. Ross [5 ]
机构：
[1] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] CHUM, Hop Notre Dame de Bon Secours, Montreal, PQ, Canada
[3] Rocky Mt Canc Ctr, Aurora, CO USA
[4] Pfizer Oncol, La Jolla, CA USA
[5] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S672 / S672
页数：1
相关论文
共 50 条
  • [21] A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies
    Bruce, Justine Yang
    Kolesar, Jill M.
    Hammers, Hans
    Stein, Mark N.
    Carmichael, Lakeesha
    Eickhoff, Jens
    Johnston, Susan A.
    Binger, Kimberly A.
    Heideman, Jennifer L.
    Perlman, Scott B.
    Jeraj, Robert
    Liu, Glenn
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 485 - 493
  • [22] A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies
    Justine Yang Bruce
    Jill M. Kolesar
    Hans Hammers
    Mark N. Stein
    Lakeesha Carmichael
    Jens Eickhoff
    Susan A. Johnston
    Kimberly A. Binger
    Jennifer L. Heideman
    Scott B. Perlman
    Robert Jeraj
    Glenn Liu
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 485 - 493
  • [23] Axitinib (AG-013736) combined with paclitaxel/carboplatin (Pac/Car), gemcitabine/cisplatin (Gem/Cis), or pemetrexed (Pem)/Cis in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors
    Kozloff, Mark F.
    Martin, Lainie P.
    Krzakowski, Maciej
    Samuel, Thomas A.
    Rado, Thomas A.
    Arriola, Edurne
    de Castro Carpeno, Javier
    Tarazi, Jamal
    Rosbrook, Brad
    Tortorici, Michael
    Olszanski, Anthony J.
    Cohen, Roger B.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S415 - S415
  • [24] Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
    P Hamberg
    N Steeghs
    W J Loos
    D van de Biessen
    M den Hollander
    M Tascilar
    J Verweij
    H Gelderblom
    S Sleijfer
    British Journal of Cancer, 2010, 102 : 1699 - 1706
  • [25] Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
    Hamberg, P.
    Steeghs, N.
    Loos, W. J.
    van de Biessen, D.
    den Hollander, M.
    Tascilar, M.
    Verweij, J.
    Gelderblom, H.
    Sleijfer, S.
    BRITISH JOURNAL OF CANCER, 2010, 102 (12) : 1699 - 1706
  • [26] Safety and Efficacy Results From ABOUND.70+: nab-Paclitaxel/Carboplatin in Elderly Patients With Advanced NSCLC
    Langer, Corey
    Goldman, Jonathan
    Amiri, Kathy
    Anderson, Eric
    DakhiLs, Shaker
    Haggstrom, Daniel
    Jotte, Robert
    Konduri, Kartik
    Modiano, Manuel
    Ong, Teng
    Sanford, Alexandra
    Smith, David
    Socoteanu, Matei
    Kim, Edward
    Weiss, Jared
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S916 - S917
  • [27] A pharmacodynamic trial of sequential sunitinib (Su) with bevacizumab (Bev) in patients (Pts) with renal cell carcinoma and other advanced solid malignancies
    Bruce, Justine Yang
    Hammers, Hans
    Kolesar, Jill
    Stein, Mark N.
    Eickhoff, Jens C.
    Carmichael, Lakeesha
    Johnston, Susan
    Perlman, Scott
    Jeraj, Robert
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [28] Preliminary results of a phase I trial of sorafenib combined with cisplatin/etoposide (CE) or carboplatin/pemetrexed (CbP) in solid tumor patients (pts)
    Dhruva, N. S.
    Stinchcombe, T. E.
    Walko, C. M.
    Socinski, M. A.
    Bernard, S.
    Kim, W. Y.
    Keller, K.
    Hilbun, L. R.
    Dees, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study
    Lustberg, M. B.
    Nuovo, J.
    Thomas, J. P.
    Monk, P. J., III
    Kim, S.
    Villalona-Calero, M.
    Bekaii-Saab, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] SUNITINIB IN COMBINATION WITH CARBOPLATIN (C) PLUS PACLITAXEL (P) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS (STS): PHASE I STUDY RESULTS
    Heath, E. I.
    Blumenschein, G. R.
    Cohen, R. B.
    LoRusso, P. Mucci
    LoConte, N.
    Kim, S. T.
    Chao, R.
    Wilding, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 156 - 156
12345